IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11186873 B1

PDFFull Text
Date of Patent:
Nov. 30, 2021

Filed:

Jul. 29, 2015

Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (igsf1) and mesenchymal-epithelial transition factor (met)

Applicant:

Wellmarker Bio Co., Ltd., Seoul, KR;

Inventors:

Dong Hoon Jin, Seoul, KR;

Seung Woo Hong, Seoul, KR;

Jai Hee Moon, Seoul, KR;

Jae Sik Shin, Seoul, KR;

Seung Mi Kim, Seoul, KR;

Dae Hee Lee, Seoul, KR;

Eun Young Lee, Seoul, KR;

Seul Lee, Seoul, KR;

Assignee:

WELLMARKER BIO CO., LTD., Seoul, KR;

Attorney:

Armstrong Teasdale LLP

Primary Examiner:

Dana H Shin

Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12Q 1/6886 (2018.01); C12Q 1/68 (2018.01); A61K 31/7088 (2006.01); A61K 31/404 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/404 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); C12N 15/1138 (2013.01); C12Q 1/68 (2013.01); C12Y 207/10001 (2013.01); G01N 33/574 (2013.01); G01N 33/57492 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70503 (2013.01);
Abstract

The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.

Find Patent Forward Citations

Loading…